20 results about "Artemether" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating atopic dermatitis and application thereof. The composition comprises the following components: pseudo-ginseng extract, artemether, alpine glycoside and oleanolic acid in a mass ratio of (2-4): (2-4): (1-2): (1-2). The composition disclosed by the invention has anti-inflammatory and anti-pruritus effects and can be used for treating atopic dermatitis, eczema and other diseases. The active components of the composition are all from plant sources, the composition has good safety and atopic dermatitis treatment efficacy, the use dosage is low, the components can achieve a synergistic interaction effect, and the composition shows an excellent effect; the composition can be applied to functional skin care products (face cream, emulsion and essence) and external medicines (applying agents and ointments).

The invention relates to the technical field of medicines, and particularly discloses an application of artemether in preparation of an esophageal cancer radiotherapy sensitization medicine. The invention provides the application of artemether in preparation of esophageal cancer radiotherapy sensitization drugs for the first time, and researches find that the artemether can reduce glycolytic activity of esophageal cancer cells by down-regulating expression of key proteins and genes HK2, PKM2 and LDHA in a glycolytic pathway so as to enhance esophageal squamous cell carcinoma radiotherapy sensitization. The invasion ability is inhibited, and cell apoptosis is induced, so that the radiotherapy sensitivity of esophageal cancer cells is enhanced. The artemether and radiotherapy combined treatment provided by the invention is expected to provide a promising treatment scheme for ESCC patients, and has great significance in breaking through the bottleneck of esophageal cancer radiotherapy.

The invention discloses an application of artemether, artesunate or dihydroartemisinin in preparation of a medicine for preventing or treating aflatoxin B1 poisoning. Belongs to the technical field of medicine. The technical problem of detoxification of aflatoxin B1 is solved. The invention provides an application of artemether, artesunate or dihydroartemisinin in preparation of a medicine for treating aflatoxin B1 poisoning diseases. The body can be promoted to detoxify the AFB1.

Compound for use in a method of treating a coronavirus infection, wherein the compound comprises Artemether, Atazanavir, Efavirenz, Fosamprenavir or Saquinavir, and wherein the method includes administering to a subject in need of the treatment an effective amount of the compound; wherein the term “compound” is inclusive of pharmaceutically acceptable salts of the compound; and wherein the coronavirus infection is an infection by a human coronavirus (e.g. SARS-CoV-2). Also claimed for use are the same compounds for use in a method of treating a coronavirus infection, or for use in a prophylaxis method to prevent Covid-19 infection. Further claimed, is compounds for use in a method of treating a coronavirus infection, wherein the compounds comprise: (A) Atazanavir, Efavirenz, Fosamprenavir, Saquinavir or Remdesivir (GS-5734); and (B) an antimalarial drug, an anti-hypertensive drug, an immunomodulatory drug, a neuroprotective drug, or an anti-inflammatory drug, each of which is as defined herein; wherein the method includes administering to a subject in need of the treatment or prophylaxis an effective amount of the compounds.

The application discloses an anti-tumor nano self-assembled particle targeting mitochondria and a preparation method and application thereof. The nano self-assembled particle takes a photothermal agent as a core and takes an active oxygen donor reagent coated on the surface of the photothermal agent as a shell. The application utilizes the photothermal agent and the active oxygen donor to prepare the nano particle through self-assembly, realizes photodynamic therapy excited by near-infrared laser, has a deeper tissue penetration depth and causes less damage to normal tissues; the active oxygen is produced by breaking a peroxide bridge in artemether, and the limitation of traditional photodynamic therapy on anoxic conditions in a tumor microenvironment is overcome; the active oxygen is produced on a subcellular level by targeting mitochondria of tumor cells; and the nano particle has self-reporting fluorescence and can realize real-time monitoring of the in-vivo distribution of the nano particle.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.

The application discloses a traditional Chinese medicine composition for treating vaginitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises 12 Chinese herbal medicines, i.e. Sophora flavescens, Phellodendron chinense, Dictamnus dasycarpus, Herba Artemisiae Scopariae, Herba Taraxaci, Chrysanthemum indicum, Herba Portulacae, Cnidium monnieri, Angelica polymorpha, Herba Verbena, Herba Menthae and Saposhnikovia divaricata, and further comprises Salix viminalis, Eucalyptus, Ephedra sinica, anthocyanin quaternary ammonium salt, Ocimum basilicum, Houttuynia cordata, polysialic acid, polydopamine, antibacterial polypeptide modified chitosan hydrochloride and artemether. The traditional Chinese medicine composition is prepared by mixing traditional Chinese medicines and bactericidal and bacteriostatic biocompatible materials to prepare various medicaments. The traditional Chinese medicine composition is used for treating pruritus and leukorrhagia caused by endogenous insect poison and burning of yin fluid, and is used for treating bacterial vaginitis, mycotic vaginitis, trichomonal vaginitis and vulvitis. In clinical tests, the traditional Chinese medicine composition has remarkable treatment effect, and the cure rate is more than 95%.

The invention discloses a preparation method of a water-soluble artemether-cyclodextrin inclusion compound and application of the water-soluble artemether-cyclodextrin inclusion compound in shampoo. The artemether-cyclodextrin inclusion compound comprises artemether, cyclodextrin and a complex, and the water solubility and quick release property of the inclusion compound are improved. The preparation method of the artemether-cyclodextrin inclusion compound comprises the following steps: respectively preparing an artemether ethanol solution and a cyclodextrin aqueous solution, mixing the two solutions, carrying out centrifugation and other treatments to form a mixed solution containing the artemether-cyclodextrin inclusion compound, and carrying out evaporation and freeze drying on the mixed solution to obtain powder of the artemether-cyclodextrin inclusion compound. Compared with monomer artemether, the clathrate has the advantages of high water solubility, quick release and the like. The inclusion compound can be used for preparing shampoo, the concentration of the inclusion compound in shampoo is 1-50 g / L, and the inclusion compound can be used for treating scalp seborrheic dermatitis and other diseases caused by pityrosporum orbiculare infection.

The invention discloses a pharmaceutical composition of artesunate and Xingnaojing and application of the pharmaceutical composition, and relates to the technical field of pharmacy, the active ingredients of the pharmaceutical composition comprise artesunate and Xingnaojing injection, and the application of artesunate and Xingnaojing injection in preparation of drugs for treating cerebral malaria. According to the application disclosed by the invention, the artesunate and Xingnaojing have a remarkable treatment effect on experimental cerebral malaria mice, and a GPR68 / cAMP / EPAC1 signal channel is activated, so that a blood brain barrier is protected, and brain tissue damage is relieved. The research provides a new drug combination strategy for clinical treatment of cerebral malaria, and lays a theoretical foundation for deep understanding of the action mechanism of cerebral malaria.

The invention discloses a compound artemether dispersible tablet and a preparation method thereof. The compound artemether dispersible tablet is prepared from the following components in parts by mass: 20 parts of artemether, 120 parts of benflumetol, 120 to 160 parts of filler, 20 to 30 parts of disintegrating agent, 5 to 15 parts of adhesive, 15 parts of lubricant and 0.5 to 2 parts of surfactant, the disintegrating agent is at least one of croscarmellose sodium, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose. According to the invention, by adopting a double disintegrating agent system (cross-linked sodium carboxymethyl cellulose and carboxymethyl starch sodium) and a surfactant (lauryl sodium sulfate), the disintegration performance and stability of the product are obviously improved, and the adopted wet mixing granulation process is simple and easy to realize industrial production; in the obtained dispersible tablet, the dissolution rate of artemether within 3 hours reaches 85% or above. The product has the advantages of rapid disintegration, good stability and the like, and is suitable for children, old people and patients with dysphagia.

The application discloses an antitumor composition of arsenic trioxide and artesunate for enhancing the drug efficacy of arsenic trioxide, and discloses GA modified pH responsive arsenic trioxide-artesunate double-drug nanoliposome including the composition, the double-drug nanoliposome including glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine polymer, cholesterol, artesunate and calcium arsenate nanoparticles; the glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine and cholesterol form nanoliposome, and the nanoliposome is loaded with artesunate and calcium arsenate nanoparticles; the calcium arsenate nanoparticles contain arsenic trioxide, and a preparation method and application in preparing antitumor drugs are disclosed. The application first co-loads the highly toxic traditional Chinese medicine arsenic trioxide and artesunate to play a synergistic effect, realizes the attenuation and efficiency enhancement of arsenic trioxide through targeted modification delivery and tumor microenvironment response release, and has a good clinical application prospect.

The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.

The invention discloses a pharmaceutical composition of artesunate combined with Xuebijing and application of the pharmaceutical composition, and relates to the technical field of pharmacy, effective components of the pharmaceutical composition comprise artesunate and Xuebijing injection, and application of the artesunate and Xuebijing injection in preparation of drugs for treating cerebral malaria. According to the application disclosed by the invention, the artesunate combined with Xuebijing has a remarkable treatment effect on experimental cerebral malaria mice, and the expression of NO is improved by activating a VEGF / Akt / eNOS signal channel, so that liver, spleen and brain tissues are protected, the immune function is recovered, and the survival rate is further improved. The research provides a new drug combination strategy for clinical treatment of cerebral malaria, and lays a theoretical foundation for deep understanding of the action mechanism of cerebral malaria.

The present application belongs to the technical field of biological medicine, and particularly relates to a composition for treating atopic dermatitis and application thereof. The mass ratio of each component of the composition is: notoginseng extract: artemether: wujin glycoside: oleanolic acid = (2-4):(2-4):(1-2):(1-2). The composition has the effects of anti-inflammation and anti-itching, and can treat atopic dermatitis, eczema and other diseases. The active ingredients of the composition are all of plant origin, have good safety and the treatment effect on atopic dermatitis, and have a low dosage. The components can achieve a synergistic effect, and show excellent effects. The composition can be applied to functional skin care products (cream, emulsion, essence) and external drugs (ointment).

The invention discloses a method for detecting dehydroartemisinin, 9-epiartemisinin and artemisinin in an artemether raw material and application thereof.The detection method comprises the step that a reference substance solution and a test solution of the artemether raw material are detected through high performance liquid chromatography, specifically, octadecylsilane chemically bonded silica is used as a filler, acetonitrile is used as a mobile phase A, the mobile phase B is used as a mobile phase C, and the mobile phase B is used as a mobile phase D; and carrying out gradient elution by taking water as a mobile phase B. The method disclosed by the invention is simple to operate, strong in specificity, good in precision and high in sensitivity, can be used for simultaneously detecting dehydroartemisinin, 9-epiartemisinin and artemisinin, and can be completely separated from four known impurities (an artemether impurity I, an artemether impurity II, dihydroartemisinin and alpha-artemether) of artemether.

The application discloses an artemether chiral amino alcohol amide derivative, a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. A series of amide compounds containing an artemisinin unit are constructed by reacting artemether with different chiral amino alcohols. The reaction is an atom-economic reaction. The preparation method has the advantages of simple operation, mild reaction, fast reaction rate, high yield and the like.

The invention relates to a composition containing artemether and a preparation method thereof. The composition comprises the following raw materials: artemether, a filler, a disintegrating agent, an adhesive, a lubricant, a solubilizer and water. The filling agent is prepared from hydroxypropyl-beta-cyclodextrin, lactose and monopotassium phosphate; the solubilizer comprises sodium oleate and laureth sorbitan. The sodium oleate and the laurel sorbitan are used as solubilizers, so that the dispersion effect of the main medicine can be improved, the content uniformity of the composition can be improved, and the curative effect of medication can be further ensured. The hydroxypropyl-beta-cyclodextrin, the lactose and the monopotassium phosphate are used as filling agents and are matched with one another, so that the hardness of the prepared composition is moderate, and the situation that the integrity of a medicine is damaged due to the fact that the composition is broken and the like in the transportation and storage processes can be avoided; and the filler can also improve the disintegration effect of the composition in the oral cavity, so that the purpose of quickly taking effect is achieved.

The invention relates to a preparation method of beta-artemether, which comprises the following steps: adding methanol and artemisinin into a container, cooling to-8-5 DEG C, adding a reducing agent in three batches, stirring and reacting for 1-3 hours to obtain dihydroartemisinin after the reducing agent is completely added, controlling the temperature to 0-10 DEG C when the central control is qualified, dropwise adding an etherifying reagent into the dihydroartemisinin, stirring for 5 minutes, adding trimethyl orthoacetate, and reacting for 1-3 hours to obtain the beta-artemether. The central control is qualified, the temperature is controlled to be 0-10 DEG C, drinking water is dropwise added, heat preservation and stirring are carried out for 1 h, filtering is carried out, an artemether crude wet product is obtained, drying is carried out, and beta-artemether is obtained. According to the preparation method, the average etherification yield is about 90%, the total etherification yield is about 85%, the crude product purity is about 99.5%, the yield is greatly improved, and the preparation cost is reduced.

The invention discloses an asymmetric hydrogel dressing with double properties and a preparation method and application thereof, and belongs to the field of biomedical materials, the asymmetric hydrogel dressing has a double-layer asymmetric structure comprising a spear layer and a shield layer; wherein the spear layer is a low-crosslinking-density layer and encapsulates liposome of targeted macrophages, the liposome contains a dimer artesunate conjugate and phosphatidylserine, and the spear layer has tissue adhesion; the shield layer is a high-crosslinking-density layer and is used for providing mechanical support and foreign matter adhesion resistance; the hydrogel dressing can synergistically release artesunate and copper ions, and strongly activates autophagy of macrophages by synergistically acting on PI3K / AKT / mTOR and AMPK / mTOR signal pathways, so that chronic inflammation is relieved, collagen deposition is promoted, and wound healing is accelerated. The invention provides an innovative intelligent dressing for treating complicated chronic wounds such as diabetic foot ulcer.